Find Clinical Trials | Cedars-Sinai

140 results found

Multiple Myeloma

ABBV-383 Compared With Standard Available Therapies in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called ABBV-383 in people with relapsed or refractory multiple myeloma (multiple myeloma that has come back or did not ...

Lung

Merck,MK-2870-019, Ph3, Open label randomized, Pembrolizumab +/- MK-2870 , NSCLC

Primary Objective: Objective: To compare MK-2870 plus pembrolizumab versus pembrolizumab monotherapy with respect to DFS as assessed by BICR. DFS: the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or ...

Pancreas

RMC-6236 Versus Standard-of-Care Therapy in Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate an experimental drug called RMC-6236 in pancreatic cancer patients whose cancer has spread outside the pancreas (metastatic) and whose cancer has returned after treatment or did not ...

Lymphoid Leukemia

AZ, D7405C00001, Ph I/II, Randomized, Rel or Refr B-Cell Acute Lymphoblastic Leukaemia, AZD0486

PART A - * Primary To assess the safety and tolerability of AZD0486 in participants with Ph(+) or Ph(-) R/R B-ALL, aged 16 to 80 years, inclusive *Secondary 1 To evaluate the preliminary efficacy of AZD0486 based on NCCN response ...

Breast, Kidney, Lung, Multiple Myeloma, Other Digestive Organ, Ovary, Pancreas ...

Nammi Therapeutics,QXL138AM-001,PhI,open,Advanced solid tumors and multiple myeloma,QXL138AM

Primary Objective: The primary objective is to characterize the safety and tolerability profile of QXL138AM in participants with advanced solid tumors or multiple myeloma. Secondary Objectives: Part A To determine the maximum tolerated dose (MTD) and/or Part B ...